Investors Hangout Stock Message Boards Logo
  • Home
  • Mailbox
  • Boards
  • Favorites
  • Whats Hot!
  • Login - Join Now!
Profile
mfglola's Profile
Displaying 1-50 of 91 result(s).
CYDY CytoDyn Inc
07/25/2025 5:47:03 PM
"given the encouraging results desc (5)
CYDY CytoDyn Inc
07/25/2025 3:55:28 PM
A Cornell Alzheimer's study... "Thi (6)
CYDY CytoDyn Inc
07/23/2025 9:11:09 PM
So FDA is now accepting application (8)
CYDY CytoDyn Inc
07/04/2025 8:49:15 AM
INmune Bio's TNF inhibitor targetin (3)
CYDY CytoDyn Inc
07/03/2025 6:57:19 PM
AstraZeneca contemplating a $15B li (13)
CYDY CytoDyn Inc
07/03/2025 1:40:53 PM
Dr. Weinberg had an oral presentati (5)
CYDY CytoDyn Inc
07/01/2025 1:45:39 PM
DSP107 + atezolizumab in 3L MSS crc (3)
CYDY CytoDyn Inc
07/01/2025 12:00:46 PM
In addition to its potential as a â (3)
CYDY CytoDyn Inc
07/01/2025 12:16:58 AM
I'm thinking, even if we doubled it (7)
CYDY CytoDyn Inc
06/05/2025 10:37:00 AM
"Pharma companies rush in to buy wh (11)
CYDY CytoDyn Inc
06/04/2025 10:49:28 PM
prostate cancer is now in stage pre (5)
CYDY CytoDyn Inc
06/02/2025 7:49:19 PM
Merck won't partner with Gilead in (2)
CYDY CytoDyn Inc
06/02/2025 3:56:59 PM
Overall Survival and Quality-of-Lif (8)
CYDY CytoDyn Inc
06/02/2025 3:43:18 PM
Sorry, I don't know how to post an (13)
CYDY CytoDyn Inc
06/02/2025 3:31:44 PM
Came across this on X. Let's hope s (1)
CYDY CytoDyn Inc
05/19/2025 12:21:27 PM
Yes, the FDA has accepted PD-L1 as (9)
CYDY CytoDyn Inc
05/17/2025 6:31:38 PM
I don't know if an ICI will ever b
CYDY CytoDyn Inc
05/16/2025 11:51:40 AM
"Upregulation of PD-L1 was seen in (7)
CYDY CytoDyn Inc
05/15/2025 9:09:22 AM
I am completely baffled as to how m (3)
CYDY CytoDyn Inc
05/13/2025 11:45:22 PM
I'm more focused on Roche, which ha (7)
CYDY CytoDyn Inc
05/02/2025 7:03:01 AM
the "50% survival level"...DIDN'T E (2)
CYDY CytoDyn Inc
04/24/2025 9:15:10 AM
What is Gilead's hope/intention by (4)
CYDY CytoDyn Inc
04/10/2025 7:36:14 PM
If not, are there other types of br (2)
CYDY CytoDyn Inc
03/26/2025 9:46:30 AM
The trial you linked must have used (2)
CYDY CytoDyn Inc
03/13/2025 10:08:08 AM
The hidden scars of ulcerative coli (9)
CYDY CytoDyn Inc
02/27/2025 3:53:01 PM
I see Dr. P will be on Steve Kirsch (4)
CYDY CytoDyn Inc
02/22/2025 5:54:11 PM
A discovery at Duke-NUS Medical Sch (14)
CYDY CytoDyn Inc
02/12/2025 11:01:01 PM
maraviroc is now a generic drug , n
CYDY CytoDyn Inc
01/27/2025 8:59:51 PM
I haven't ran across any studies lo (8)
CYDY CytoDyn Inc
01/27/2025 8:32:33 AM
Agenus' botensilimab/balstilimab co (4)
CYDY CytoDyn Inc
01/10/2025 8:39:05 AM
Mediar Therapeutics Enters into Glo (7)
CYDY CytoDyn Inc
01/08/2025 6:16:03 PM
Calico’s fosigotifator was tested (4)
CYDY CytoDyn Inc
12/15/2024 1:39:02 PM
Maybe I missed it, but I don't reme (3)
CYDY CytoDyn Inc
12/12/2024 7:41:59 PM
I'm sure he's very aware of the sto (3)
CYDY CytoDyn Inc
12/09/2024 8:45:57 AM
And playing six degrees of leronlim (8)
CYDY CytoDyn Inc
12/06/2024 8:09:36 PM
Maybe it is the Gates Foundation th (14)
CYDY CytoDyn Inc
11/22/2024 3:39:58 PM
The dosing schedule should be and t (2)
CYDY CytoDyn Inc
11/14/2024 11:26:32 PM
I think someone (Ohm?) should make (3)
CYDY CytoDyn Inc
11/13/2024 2:34:34 PM
Upregulation of CCL4 after treatmen (6)
CYDY CytoDyn Inc
11/05/2024 6:59:00 AM
Surrogate reads like anecdotal is b (4)
CYDY CytoDyn Inc
10/31/2024 9:07:29 PM
HOW are they able to showcase "slow (6)
CYDY CytoDyn Inc
10/31/2024 11:20:29 AM
What is a bit strange is that they (1)
CYDY CytoDyn Inc
10/30/2024 8:40:24 AM
Familial ALS? I'm so sorry. That mu (3)
CYDY CytoDyn Inc
10/30/2024 7:01:05 AM
Coya yesterday reported their low d (2)
CYDY CytoDyn Inc
10/29/2024 8:36:20 PM
I would expect academic institution (7)
CYDY CytoDyn Inc
10/29/2024 10:54:47 AM
Ohm - do you discount the possibili (4)
CYDY CytoDyn Inc
10/28/2024 8:19:27 AM
At a townhall in Lancaster PA, Elon (13)
CYDY CytoDyn Inc
10/19/2024 6:16:10 PM
A fascinating conversation on ccr5 (6)
CYDY CytoDyn Inc
10/11/2024 12:33:51 PM
Findings may guide future Parkinson (5)
CYDY CytoDyn Inc
10/06/2024 2:11:04 PM
Since it is an open label study, it (6)
Go to page:
  • << First
  • < Previous
  • 1
  • 2
  • Next >

Recent Articles

  • Transformative Growth in Xizang's Peach Blossom Village
  • VINCI Secures Major Eastern Freeway Upgrade Contract
  • Exploring Renewable Natural Gas Initiatives by Southwest Gas
  • Future Growth and Trends in the U.S. Glass Cleaner Market
  • Florida Cancer Specialists Enhances Radiation Oncology Services
  • Join Niccolo de Masi at the Entrepreneur Expo for Innovation
  • Vaisala Corporation Engages in Share Repurchase Initiative
  • Fausak Tires & Service Expands with New Alabama Location
  • Understanding the Current Market Sentiment for Teva Pharma
  • Innovative Post Driver Enhances Safety and Efficiency
  • Understanding Investor Sentiment on Stifel Financial's Stock
  • Class Action Lawsuit Filed Over Unpaid Overtime Wages
  • Analyzing Market Trends Surrounding Chipotle Mexican Grill
  • Class Action Filed Against Heritage Hotel Group Over Wages
  • Duolingo Optimizes Learning Experience with AI Enhancements
  • Globant Unveils Revolutionary Enterprise AI 2.0 Platform
  • Opendoor Technologies Embraces Meme Madness: What’s Next?
  • Envestnet Welcomes John Hofmann as New CFO for Growth
  • Investing in Boston Scientific: A Decade of Strong Returns
  • Class Action Against Island Snacks, Inc. Highlights Labor Law Violations
  • Home Depot Sets Stage for Strong Q2 Earnings Amid Market Challenges
  • California Freight Sales Faces Class Action for Labor Violations
  • Car and Driver Marketplace Launches for Streamlined Car Shopping
  • Black Buffalo Inc. Celebrates Recognition on Inc. 5000 List
  • OMI Pulse Receives ASCO Recognition for Quality Solutions
  • Corporate Technologies Expands National Presence with Cenetric Deal
  • HiLabs Strengthens Cybersecurity with HITRUST i1 Certification
  • Century Complete Introduces Stunning Roanoke Model Home Today
  • Discover the Magical Taste at the Harry Potter x Coffee Mate Cafe
  • Investing in Celsius Holdings: A 5-Year Financial Journey
  • Unicycive Therapeutics Faces Legal Challenge: Key Insights
  • Spectrum Pharmaceuticals Faces Class Action Deadline for Investors
  • Nvidia's Vision: Projected Revenue Surge to $300 Billion by 2026
  • Mark Cuban Foundation Hosts Free AI Bootcamp for Teens
  • Mark Cuban Foundation's AI Bootcamp: Empowering Omaha Youth
  • Local Marine Supply Business Welcomes New Investment for Growth
  • Insight into Premier's Upcoming Earnings and Market Presence
  • Ituran Location & Control: Earnings Predictions and Insights
  • Roadzen Clarifies Analyst Expectations Amid Q1 FY2026 Results
  • Upcoming Earnings Preview for Opera and Its Market Impact
  • Anticipating Auna's Earnings Report and Future Outlook
  • SFL Corp's Earnings Report: What Investors Should Know
  • Anticipating La-Z-Boy's Upcoming Earnings Announcement
  • What Investors Need to Know About Evogene's Earnings Call
  • Ellington Credit's Earnings Forecast: Key Insights for Investors
  • Insights on Fluent's Financial Outlook for Investors
  • Exciting Launch: SKITTLES Gummies Fuego Adds Swicy Flavors
  • Earnings Outlook for Datavault AI Inc. - What Investors Should Know
  • SweetScience: A Visionary Marketing Agency Joins MEC Community
  • OS Therapies Earnings: Insights and Expectations for Investors
  • Home - Investors HangoutHome

  • Mailbox - Investors HangoutMailbox

  • Boards - Investors HangoutBoards

  • Favorites - Investors HangoutFavorites

  • Whats Hot! - Investors HangoutWhats Hot!

  • More - Investors HangoutMore

  • Settings - Investors HangoutSettings
  • Login - Investors HangoutLogin
  • Live Site - Investors HangoutLive Site